cyrilzakka/clinical-trials huggingface dataset:
Recurrent Pneumonia in Children

This study aimed to analyses the clinical characteristics, risk factors and underlying causes as predictors of recurrent pneumonia in children attending AUCH

Pneumonia is defined as inflammation of lung parenchyma due to various pathogenic organisms including bacteria, viruses, fungi and parasites. The key symptom to suspect childhood pneumonia is tachypnea. The World Health Organization (WHO) has defined tachypnea as respiratory rate \>60 breaths/min in infants less than 2 months, \>50 in infants 2 -12 months and \>40 in children 1 to 5 years and \>20 in children \>5 years of age \[1\]. WHO has categorized pneumonia in children under-five years of age into two categories, pneumonia and severe pneumonia. Tachypnea with or without chest retraction is categorized as pneumonia while tachypnea with any danger signs (unable to feed or drink, hypothermia, unconsciousness, convulsion, signs of hypoxia including cyanosis, grunting, groaning, head nodding) as severe pneumonia \[1\].

Pneumonia is a common and described as the overlooked killer of children\[2\] as killing 1.1-1.4 million children every year. It accounts for 17%-19% of all deaths amongst children under 5 years of age; the majority of them are in developing countries \[3,4\] .In Egypt, children under 5 years approximate 13.4% of the total population\[4\] and pneumonia constitutes 19% of under-five mortality\[5\].

Recurrent pneumonia (RP) is defined as at least two episodes of pneumonia in one year or three episodes ever, with intercritical radiographic clearing of densities \[6\]. Incidence data indicate that RP occurs in 7.7%-9% of all children with CAP \[7,8,9,10,11,12\]. As a result, RP represents a frequent presenting manifestation in the general pediatric practice and is a very common reason for referral to pediatric chest physicians \[7\]. Factors linked to these infections could be recurrent aspirations, congenital structural anomalies of pulmonary and cardiovascular systems, defects in the clearance of airway secretions and immunodeficiency \[13\]

Eligibility Criteria:
Inclusion Criteria:

* • All children more than 1 month and less than 18 years of age

  * All cases presented by picture of recurrent pneumonia in the form of as at least two episodes of pneumonia in one year or three episodes ever, with radiographic clearing of densities in between.

Exclusion Criteria:

* • All children less than 1 month and more than 18 years

  * Evidence of malignancies
  * Evidence of congenital immune deficiency
  * Cases refusing to participate in research.
  * Cases missed for follow up.
Validation of an Intracycle CT Motion CORrection Algorithm for Diagnostic AccuracY

To demonstrate the incremental utility of SSF for individuals undergoing CCTA, with expected improvements in image quality and diagnostic accuracy.

Hypothesis: Coronary CT angiography (CCTA) employing a novel intracycle motion compensation algorithm (SnapShot Freeze \[SSF\]) will be superior to CCTA without an intracycle motion compensation algorithm ("conventional" CCTA) for diagnostic accuracy and image quality.

Scientific Basis: Preliminary study (Leipsic, Min, Journal of Cardiovascular Computed Tomography \[in press\]) of coronary CT angiograms in individuals undergoing pre-procedural assessment for transcatheter aortic valve replacement (n=36) demonstrate improved image quality of CCTA using SSF compared to CCTA not using SSF. Importantly, individuals in this study did not receive heart rate slowing agents (e.g., beta blockers), and diagnostic image quality was substantially improved. While not statistically powered on a per-patient basis, per-segment diagnostic accuracy of CCTA using SSF was superior to conventional CCTA. These results are complementary to those derived from internal testing at GE Healthcare wherein phantom work has demonstrated improved diagnostic performance using SSF compared to conventional image acquisitions.

Long-term Goal/Purpose: To demonstrate the incremental utility of SSF for individuals undergoing CCTA, with expected improvements in image quality and diagnostic accuracy. If the aims of this study are achieved, the use of SSF for effective temporal resolution improvement may obviate (or reduce) the need for CT hardware for improved temporal resolution.

Eligibility Criteria:
Inclusion Criteria:

1. Consenting adult patients ≥18 years of age;
2. Suspected but without known prior history of CAD
3. Not actively taking heart rate lowering agents at least 48 hours prior to study (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)
4. Glomerular filtration rate \>60 ml/min
5. CCTA and ICA within 1 week of each other with no interscan event (e.g., myocardial infarction or coronary revascularization)

Exclusion Criteria:

1. Incomplete ICA or CCTA;
2. Known CAD (prior myocardial infarction, PCI, CABG)
3. Atrial Fibrillation
4. Abnormal Renal Function (GFR \<60 ml/min)
5. Unwilling or unable to give consent
6. Non-cardiac illness with life expectancy \<1 year
7. Concomitant participation in another clinical trial in which subject is subject to investigational drug or device
8. Pregnant women
9. Allergy to iodinated contrast agent
10. Contraindications to nitroglycerin
11. Systolic blood pressure ≤90 mm Hg
12. Contraindications to β blockers or nitroglycerin
The Short-term Effects of Trunk Kinesio Taping on Trunk Muscle Endurance and Postural Stability in Healthy Young Adults

This study aimed to investigate the short-term effects of trunk kinesio taping on trunk muscle endurance and postural stability in healthy young adults.


Eligibility Criteria:
Inclusion Criteria:

* Healthy young volunteers aged between 18-25 years

Exclusion Criteria:

* Having disc hernias, any spinal pain complaint, spinal deformity, history related to spinal surgery, vestibulopathy, musculoskelatal injuries related to ankle, knee and hip joints, orthopedic and/or neurological problems and allergy to the kinesio tape
Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults

It involves collecting safety and efficacy data, under the actual conditions of use of medicines in children and adolescents, using a validated tool (Ennov EDC) and relying on the network of Interregional pediatric oncology appeal organizations (RIOs) identified by INCa since 2010 and responsible for the organization of Pluridisciplinary Pediatric Interregional (RCPPI) and National Consultative Meetings which discuss each case of relapse in order to define the best therapeutic options.

The objective is to aim for completeness throughout the national territory. This is why this project will be carried out in close collaboration with the RIOs and RCPPI and that of the 31 centers of the SFCE which bring together more than 400 doctors pediatric oncologists and hematologists on the French territory

Eligibility Criteria:
Inclusion Criteria:

* Age ≤ 25 years old at the time of inclusion in the study
* Patient with a pediatric tumor or leukemia in therapeutic failure or relapse without standard therapeutic options. Exceptionally, patients on the first line of treatment without standard therapeutic options may also be included (eg g: inoperable plexiform neurofibroma and MEK inhibitors, childhood fibrosarcoma and NTRK inhibitors).
* Patient not eligible for an early phase clinical trial open to inclusion on French territory or refusal of inclusion
* Patient treated with a new drug discussed at a RCPPI as part of a compassionate use issued by the ANSM or an off-label prescription of a drug of interest already authorized in adults.
* Patients treated in one of the SFCE centers authorized to prescribe chemotherapy
* Patient who did not object to participate after being informed of the study. The patient must be able and willing to cooperate in the study.

Exclusion Criteria:

* Patient included in an early phase clinical trial open to inclusions on French territory.
* Oral refusal to participate by the patient or their legal representatives, in reading the information note specific to the study
* Patient under guardianship or curatorship, deprived of liberty or in the impossibility of expressing opposition to participating in the study
Correlation Between Maternal Vitamin D Level And Preterm Birth

Assessment of correlation between vitamin D level and prevalence of preterm births remains limited. The exact role of vitamin D in preterm birth has not yet been clearly defined ,where some studies showed vitamin D deficiency increased the risk of preterm birth while other studies found no correlation. In this study will try to continue research on this subject.


Eligibility Criteria:
Inclusion Criteria:

* Singleton gestation.
* Maternal age: 20-35 years.

Exclusion Criteria:

1. Multi fetal pregnancy.
2. Anatomical or genetic defect of the fetus.
3. Iatrogenic preterm delivery.
4. Maternal medical disorder e.g diabetes millets (D.M).
5. Antepartum hemorrhage.
6. Hypertensive disorders.
7. Polyhydromins or oligolydromins
8. Premature rupture of membranes ± Chorioamnionitis
9. Incompetent cervix.
10. Post IVF.
11. Uterine Fibroid or malformation.
Comparison of Amikacin Lung Delivery With Two Nebulizers

Comparison between two modalities of nebulization.


Eligibility Criteria:
Inclusion Criteria:

* Male healthy subjects
* Cystic fibrosis

Exclusion Criteria:

* Kidney failure
* No pregnancy
Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse

The purpose of this study is to assess the abuse liability of 4 times (8 tablets) the usual recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40 mg alone in subjects with a history of opioid abuse.

In the Treatment Phase, subjects randomly received oxycodone HCl 40 mg administered in combination with niacin 240 mg and oxycodone HCl 40 mg alone in crossover design. 15 subjects were randomized to receive oxycodone/niacin first followed by oxycodone with a 48 hour washout between doses. 15 subjects randomized to receive oxycodone before the oxycodone/naicin dose with a 48 hour washout between doses. The purpose of the Treatment Phase was to assess the abuse liability and abuse deterrence potential of 4 times the recommended 2-tablet dose of Acurox® Tablets 5/30 mg versus oxycodone HCl 40 mg alone (8 tablets per dose).

All 30 subjects received a single dose of each study treatment. Subjects were fasted prior to dosing on all dose days.

Eligibility Criteria:
Inclusion Criteria:

* Subject is male or female between 18 and 55 years of age
* Subject meets DSM-IV Criteria for the Diagnosis of Opioid Substance Abuse and subject is unlikely to experience an idiosyncratic reaction or respiratory depression after ingesting 40 mg of oxycodone
* Body weight is not more than 20% above or below ideal body weight
* Subject agrees to abstain from any Rx or OTC drugs (except as authorized by the Investigator) or alcohol
* Subject is in generally good health
* Subject is reliable, willing, cooperative, able to communicate effectively, and has a minimum of a 6th grade reading level
* Subject has an acceptable score on the MMSE for cognitive impairment
* For women of child-bearing potential: woman is not pregnant and not nursing, and is practicing an acceptable method of birth control

Exclusion Criteria:

* Subject has a disease that may endanger the subject or the validity of the data
* Subject is currently physically dependent on opiates or alcohol
* Subject was exposed to any investigational drug within 30 days prior to the inpatient phase
* Subject has a history of hypersensitivity to any drug, or a known allergy to any component of the study drug formulation
* Subject has a positive urine drug screen for a non-opiate drug
* Subject has a predisposing condition that may place the subject at risk for receiving niacin or oxycodone, or confound the study analyses
* Subject ingested niacin at doses higher than SDI within 14 days prior to the inpatient phase
* Subject has an abnormal bleeding tendency
Risperdal Consta and Health Care Utilization in Patients With Schizophrenia

The purpose of this study is to determine if Risperdal Consta will affect the healthcare utilization costs in chronically ill schizophrenic patients with multiple admissions to the psychiatric hospital compared to the previous utilization costs under standard oral treatment of any atypical antipsychotic. We hypothesize that higher Risperdal Consta acquisition costs can be offset by reduction in total medical utilization costs, such as hospitalizations, ER visits, unscheduled outpatient visits or incarcerations due to worsening of psychotic symptoms.


Eligibility Criteria:
Inclusion Criteria:

* Primary diagnosis of schizophrenia or schizoaffective disorder
* 4 or more admissions to psychiatric hospital in past year, OR minimum of 2 hospital admissions and at least 2 incarcerations in the previous year
* Medicaid recipient
* Patients requiring concomitant non-antipsychotic psychotropic medication (mood stabilizing, antidepressants, anxiolytics)

Exclusion Criteria:

* Past or current psychiatric disorder, other than schizophrenia or schizoaffective disorder
* Drug or alcohol dependence
* Serious, unstable medical illness or any acute medical condition
* Pregnant or lactating females
* Prior Risperdal Consta treatment
* Non-English speaking
Effect of Breathıng Exercıse Applıed to Indıvıduals Wıth Copd on Respıratory Functıon, Dyspnea and Qualıty of Lıfe

Purpose of the research This research was designed to determine the effect of breathing exercise applied to individuals diagnosed with COPD on respiratory function, dyspnea and quality of life.

Hypotheses of the Research H0a: Breathing exercise applied to individuals diagnosed with COPD has no effect on the respiratory function test FEV1/FVC.

H1a: Breathing exercise applied to individuals diagnosed with COPD has an effect on the respiratory function test FEV1/FVC.

H0b: Breathing exercise applied to individuals diagnosed with COPD has no effect on dyspnea.

H1b: Breathing exercise applied to individuals diagnosed with COPD has an effect on dyspnea.

H0c: Breathing exercise applied to individuals diagnosed with COPD has no effect on quality of life.

H1c: Breathing exercise applied to individuals diagnosed with COPD has an effect on the quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with COPD for at least 1 year, confirmed by pulmonary function test
* Those who voluntarily accepted to participate in the research
* Those aged 18 and over,
* Individuals who have access to the hospital

Exclusion Criteria:

* In COPD exacerbation period,
* Having a neurological or psychiatric diagnosis,
* Those with obesity,
* Those with physical disabilities (vision, hearing, walking, etc.),
* Those who are pregnant,
* Illiterate
* Diagnosed with another disease that significantly affects the respiratory system (scoliosis, lung cancer, abdominal tumor, etc.).
* Patients who have previously participated in an exercise program will be excluded from the study.
A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status

To determine EGFR mutation status in patients with advanced stage adenocarcinoma NSCLC.

To determine the association between EGFR mutation status and demographic data in advanced stage adenocarcinoma NSCLC patients.


Eligibility Criteria:
Inclusion Criteria:

Nil

Exclusion Criteria:

Nil
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

This is a single-arm, multi-center, open-label phase 2 study of the SINE™ compound selinexor given orally to patients with relapsed or refractory PTCL or CTCL.

Approximately 60 patients with relapsed or refractory PTCL or CTCL who meet the eligibility criteria and have none of the exclusion criteria will be enrolled to receive selinexor until either disease progression or intolerance has occurred.

This is a single-arm, multi-center, open-label phase 2 study of the SINE™ compound selinexor given orally to patients with relapsed or refractory PTCL or CTCL.

Approximately 60 patients with relapsed or refractory PTCL or CTCL who meet the eligibility criteria and have none of the exclusion criteria will be enrolled to receive selinexor until either disease progression or intolerance has occurred.

Enrolled patients will be given selinexor as an oral fixed 60 mg dose (equivalent to \~35 mg/m²) on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (total 8 doses per cycle).

There is no maximum treatment duration. Patients will receive supportive therapy to mitigate selinexor side effects, as well as best supportive care (BSC).

Patients enrolled under Protocol Versions \<3.0 were to receive selinexor orally, at a fixed dose of 60 mg (equivalent to \~35 mg/m²) on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (total of 6 doses per cycle). Selinexor was not taken during Week 4.

For all patients enrolled in this study (regardless of the protocol version) who continued onto Cycle 3 and forward, the dose was to be increased by 20 mg to 80 mg (administered on Days 1 and 3 of Weeks 1-4), only after consultation with the Sponsor's Medical Monitor.

Eligibility Criteria:
Inclusion Criteria:

* ECOG performance status of ≤2.
* Relapsed or refractory disease to at least one prior systemic regimen.
* Measurable disease: according to International Working Group (IWG) guidelines for all patients with PTCL and according to CTCL Response in Skin consensus criteria for all patients with CTCL.
* Objective, documented evidence of disease progression on study entry.

Exclusion Criteria:

* Known active central nervous system (CNS) lymphoma.
* Active graft-versus-host disease after allogeneic stem cell transplantation. At least 4 months must have elapsed since completion of allogeneic stem cell transplantation.
* Unable to swallow tablets or malabsorption syndrome, disease significantly affecting gastrointestinal function.
Prognosis of Heart Transplanted Patients With Heart Failure

Heart transplantation is the most effective treatment for end-stage heart failure, advanced cardiomyopathy, and complex congenital heart disease with severe heart failure or hypoxia. Several clinical studies have shown significant differences in the prognosis of heart transplantation patients with different etiologies, and post-transplantation complications are an important factor affecting patient survival, and there is still a lack of overall prognostic stratification and extensive clinical studies on risk factors after heart transplantation. Therefore, this study is intended to include patients who underwent heart transplantation for different etiologies of heart failure, collect clinical data and biological samples from patients, and use various techniques to deeply interpret the risk factors affecting the prognosis of heart transplantation patients and construct a prognostic prediction model to provide specific and individualized treatment ideas and theoretical basis for improving the survival rate of patients after heart transplantation.


Eligibility Criteria:
Inclusion Criteria:

* Patients with end-stage heart failure presented to our hospital who are evaluated by clinicians and ethically approved for heart transplantation
* Individuals whose hearts are donated

Exclusion Criteria:

* Patients refuse to sign informed consent form
A Pharmacodynamic and Pharmacokinetic Study of RO5508887 in Healthy Volunteers

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the pharmacodynamics and pharmacokinetics of RO5508887 in healthy volunteers.

Subjects will be randomized in cohorts to receive single oral doses of either RO5508887 or placebo. In-unit period is 6 days.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male subjects, 18 to 65 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and a complete physical examination
* Body mass index (BMI) 18 to 30 kg/m2 inclusive
* Must agree to use a barrier method of contraception during the treatment period and for at least 30 days after the last dose of study drug
* Donation of blood over 500 mL within 6 weeks before drug administration

Exclusion Criteria:

* Concomitant disease or condition or treatment that could interfere with the conduct of the study or would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
* Allergy to lidocaine
* Suspicion of regular consumption of drug of abuse
* Regular smoker (\> 5 cigarettes, \> 1 pipeful or \> 1 cigar per day)
* Positive for hepatitis B, hepatitis C or HIV 1 or 2 infection
* Participation in an investigational drug or device study (last administration of study drug or installation of device) within 6 weeks before RO5508887 administration and within 5 mean half-lives of receiving previous investigational drug before RO5508887 administration. In addition, subject cannot participate unless completely recovered from previous invasive or study procedure
* Donation of blood over 500 mL within 6 weeks before drug administration
Evaluation of the Effectiveness of Surgical Treatment of Villo-nodular Synovitis of the Hip in Children

Villo-nodular synovitis can affect the joints, bursae or tendon sheaths. This condition is rare, with 1.8 cases per million inhabitants. The hip is affected in 3.6 to 18.1% of cases. The age of predilection is between 30 and 50 years old and this condition is rarely described in children.

Two articles report a case of villous-nodular synovitis of the child's hip. Surgical treatment by resection seems to be consensus but various adjuvant treatments are also proposed. A case of villous-nodular synovitis of the hip in children was treated without surgical intervention. The main objective of this study was to evaluate the efficacy of surgical treatment of villous nodular synovitis of the hip in children.

French multicentric cases serie

Eligibility Criteria:
Inclusion Criteria:

* Children with histologically villo-nodular synovitis of the hip
* Surgical procedures performed for the treatment of this synovitis

Exclusion Criteria:

* Degree of bone maturation and Risser test greater than 4 at the time of diagnosis
* Parents opposing the use of their child's data / Patient opposing the use of his/her data
Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men

This is a pilot study of a new 9-session individually delivered cognitive behavioral intervention targeting sexual minority stress. In this study, 40 HIV+ men sexual minority men will be recruited for the study then will be randomly assigned to either the new 9 session intervention or a writing task condition.


Eligibility Criteria:
Inclusion Criteria:

* Provide evidence or documentation of HIV positive status (e.g. a letter of diagnosis or medication bottles with matched photo ID)
* Be English speaking
* Be able to consent
* Sexual activity with a man in the 3 years prior to initial contact or identification as gay or bisexual
* Not currently be enrolled in formal substance abuse treatment
* Report at least one occasion of drinking 5 or more drinks or of using an illicit substance in the previous 3 months, but not meet criteria for a severe substance use disorder.

Exclusion Criteria:

* Presence of a severe substance use disorder
* Presence of current symptoms consistent with schizophrenia or bipolar disorder, which would indicate that an intervention targeting these symptoms would be more appropriate.